


## Figure


### Caption

Verifying the MACE-associated serum analyte with  $m/z = 153.0656$  Da is comprised of 2PY and 4PY. The MACE-associated serum analyte with  $m/z = 153.0656$  Da was resolved into two chromatographically separable structural isomers, 2PY and 4PY, using the new HPLC method. The two analytes have retention times of 2.4 min (metabolite 1; 2PY) and 3.4 min (metabolite 2; 4PY). (a) High resolution CID spectrum of serum metabolite 1 with retention time 2.4 min compared to synthetic 2PY (retention time 2.4 min). Peaks are labeled with their measured  $m/z$  in Da. (b) Sizes of predicted fragments of 2PY. Predicted fragments are labeled with their predicted  $m/z$  in Da. (c) CID spectrum of metabolite 2 with retention time 3.4 min compared to synthetic 4PY (retention time 3.4 min). Peaks are labeled with their measured  $m/z$  in Da. (d) Sizes of predicted fragments of 4PY. Predicted fragments are labeled with their predicted  $m/z$  in Da. Chemical synthesis of 2PY and 4PY is described in Supplemental Methods, and  $^1\text{H-NMR}$  spectra of synthetic material are shown in Supplemental Figs. 1 and 2. Differences in  $m/z$  among predicted fragments and those observed for synthetic and serum 2PY and 4PY were within expected experimental error and are shown in Supplemental Table 6. Source data

Content available from [Nature Medicine](#). This content is subject to copyright. [Terms and conditions](#) apply.



	4PY	2PY	Age	LDL	HDL	TG	hsCRP
eGFR	-0.27 **	-0.24 **	-0.59 **	0.10 **	-0.18 **	-0.026	-0.09 **
hsCRP	0.050 *	0.055 *	0.018	0.072 *	-0.15 **	0.18 **	
TG	0.005	0.011	-0.12 **	0.21 **	-0.26 **		
HDL	-0.17 **	-0.17 **	0.27 **	0.13 **			
LDL	-0.11 **	-0.088 **	-0.13 **				
Age	0.076 **	0.051 *					
2PY	0.90 **						




## Figure


### Caption

Verifying the MACE-associated serum analyte with  $m/z = 153.0656$  Da is comprised of 2PY and 4PY. The MACE-associated serum analyte with  $m/z = 153.0656$  Da was resolved into two chromatographically separable structural isomers, 2PY and 4PY, using the new HPLC method. The two analytes have retention times of 2.4 min (metabolite 1; 2PY) and 3.4 min (metabolite 2; 4PY). (a) High resolution CID spectrum of serum metabolite 1 with retention time 2.4 min compared to synthetic 2PY (retention time 2.4 min). Peaks are labeled with their measured  $m/z$  in Da. (b) Sizes of predicted fragments of 2PY. Predicted fragments are labeled with their predicted  $m/z$  in Da. (c) CID spectrum of metabolite 2 with retention time 3.4 min compared to synthetic 4PY (retention time 3.4 min). Peaks are labeled with their measured  $m/z$  in Da. (d) Sizes of predicted fragments of 4PY. Predicted fragments are labeled with their predicted  $m/z$  in Da. Chemical synthesis of 2PY and 4PY is described in Supplemental Methods, and  $^1\text{H}$ -NMR spectra of synthetic material are shown in Supplemental Figs. 1 and 2. Differences in  $m/z$  among predicted fragments and those observed for synthetic and serum 2PY and 4PY were within expected experimental error and are shown in Supplemental Table 6. Source data

Content available from [Nature Medicine](#). This content is subject to copyright. [Terms and conditions](#) apply.



	4PY	2PY	Age	LDL	HDL	TG	hsCRP
eGFR	-0.27 **	-0.24 **	-0.59 **	0.10 **	-0.18 **	-0.026	-0.09 **
hsCRP	0.050 *	0.055 *	0.018	0.072 *	-0.15 **	0.18 **	
TG	0.005	0.011	-0.12 **	0.21 **	-0.26 **		
HDL	-0.17 **	-0.17 **	0.27 **	0.13 **			
LDL	-0.11 **	-0.088 **	-0.13 **				
Age	0.076 **	0.051 *					
2PY	0.90 **						




## Figure

### Caption

Verifying the MACE-associated serum analyte with  $m/z = 153.0656$  Da is comprised of 2PY and 4PY. The MACE-associated serum analyte with  $m/z = 153.0656$  Da was resolved into two chromatographically separable structural isomers, 2PY and 4PY, using the new HPLC method. The two analytes have retention times of 2.4 min (metabolite 1; 2PY) and 3.4 min (metabolite 2; 4PY). (a) High resolution CID spectrum of serum metabolite 1 with retention time 2.4 min compared to synthetic 2PY (retention time 2.4 min). Peaks are labeled with their measured  $m/z$  in Da. (b) Sizes of predicted fragments of 2PY. Predicted fragments are labeled with their predicted  $m/z$  in Da. (c) CID spectrum of metabolite 2 with retention time 3.4 min compared to synthetic 4PY (retention time 3.4 min). Peaks are labeled with their measured  $m/z$  in Da. (d) Sizes of predicted fragments of 4PY. Predicted fragments are labeled with their predicted  $m/z$  in Da. Chemical synthesis of 2PY and 4PY is described in Supplemental Methods, and  $^1\text{H-NMR}$  spectra of synthetic material are shown in Supplemental Figs. 1 and 2. Differences in  $m/z$  among predicted fragments and those observed for synthetic and serum 2PY and 4PY were within expected experimental error and are shown in Supplemental Table 6. Source data

Content available from [Nature Medicine](#). This content is subject to copyright. [Terms and conditions](#) apply.



	4PY	2PY	Age	LDL	HDL	TG	hsCRP
eGFR	-0.27 **	-0.24 **	-0.59 **	0.10 **	-0.18 **	-0.026	-0.09 **
hsCRP	0.050 *	0.055 *	0.018	0.072 *	-0.15 **	0.18 **	
TG	0.005	0.011	-0.12 **	0.21 **	-0.26 **		
HDL	-0.17 **	-0.17 **	0.27 **	0.13 **			
LDL	-0.11 **	-0.088 **	-0.13 **				
Age	0.076 **	0.051 *					
2PY	0.90 **						


Spearman Rho

## Figure

### Caption

Verifying the MACE-associated serum analyte with  $m/z = 153.0656$  Da is comprised of 2PY and 4PY. The MACE-associated serum analyte with  $m/z = 153.0656$  Da was resolved into two chromatographically separable structural isomers, 2PY and 4PY, using the new HPLC method. The two analytes have retention times of 2.4 min (metabolite 1; 2PY) and 3.4 min (metabolite 2; 4PY). (a) High resolution CID spectrum of serum metabolite 1 with retention time 2.4 min compared to synthetic 2PY (retention time 2.4 min). Peaks are labeled with their measured  $m/z$  in Da. (b) Sizes of predicted fragments of 2PY. Predicted fragments are labeled with their predicted  $m/z$  in Da. (c) CID spectrum of metabolite 2 with retention time 3.4 min compared to synthetic 4PY (retention time 3.4 min). Peaks are labeled with their measured  $m/z$  in Da. (d) Sizes of predicted fragments of 4PY. Predicted fragments are labeled with their predicted  $m/z$  in Da. Chemical synthesis of 2PY and 4PY is described in Supplemental Methods, and  $^1\text{H}$ -NMR spectra of synthetic material are shown in Supplemental Figs. 1 and 2. Differences in  $m/z$  among predicted fragments and those observed for synthetic and serum 2PY and 4PY were within expected experimental error and are shown in Supplemental Table 6. Source data

Content available from [Nature Medicine](#). This content is subject to copyright. [Terms and conditions](#) apply.



## Figure

### Caption

Verifying the MACE-associated serum analyte with  $m/z = 153.0656$  Da is comprised of 2PY and 4PY. The MACE-associated serum analyte with  $m/z = 153.0656$  Da was resolved into two chromatographically separable structural isomers, 2PY and 4PY, using the new HPLC method. The two analytes have retention times of 2.4 min (metabolite 1; 2PY) and 3.4 min (metabolite 2; 4PY). (a) High resolution CID spectrum of serum metabolite 1 with retention time 2.4 min compared to synthetic 2PY (retention time 2.4 min). Peaks are labeled with their measured  $m/z$  in Da. (b) Sizes of predicted fragments of 2PY. Predicted fragments are labeled with their predicted  $m/z$  in Da. (c) CID spectrum of metabolite 2 with retention time 3.4 min compared to synthetic 4PY (retention time 3.4 min). Peaks are labeled with their measured  $m/z$  in Da. (d) Sizes of predicted fragments of 4PY. Predicted fragments are labeled with their predicted  $m/z$  in Da. Chemical synthesis of 2PY and 4PY is described in Supplemental Methods, and  $^1\text{H-NMR}$  spectra of synthetic material are shown in Supplemental Figs. 1 and 2. Differences in  $m/z$  among predicted fragments and those observed for synthetic and serum 2PY and 4PY were within expected experimental error and are shown in Supplemental Table 6. Source data

Content available from [Nature Medicine](#). This content is subject to copyright. [Terms and conditions](#) apply.

